

Exhibit C

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

CIVIL ACTION NUMBER:

IN RE: VALSARTAN PRODUCTS
LIABILITY LITIGATION

19-md-02875-RBK-JS

TELEPHONIC STATUS
CONFERENCE WITH ORAL
ARGUMENT AND RULINGS ON
DEFENDANTS' FACT SHEETS

Mitchell H. Cohen Building & U.S. Courthouse
4th & Cooper Streets
Camden, New Jersey 08101
July 29, 2020
Commencing at 10:20 a.m.

B E F O R E:

THE HONORABLE JOEL SCHNEIDER,
UNITED STATES MAGISTRATE JUDGE
AND
THE HONORABLE ROBERT B. KUGLER,
UNITED STATES DISTRICT JUDGE

A P P E A R A N C E S:

MAZIE SLATER KATZ & FREEMAN, LLC
BY: ADAM M. SLATER, ESQUIRE
103 EISENHOWER PARKWAY
ROSELAND, NEW JERSEY 07068
For the Plaintiffs

GOLOMB & HONIK, P.C.
BY: RUBEN HONIK, ESQUIRE
1835 MARKET STREET, SUITE 2900
PHILADELPHIA, PENNSYLVANIA 19103
For the Plaintiffs

LEVIN PAPANTONIO THOMAS MITCHELL RAFFERTY PROCTOR P.A.
BY: DANIEL A. NIGH, ESQUIRE
316 S. BAYLEN, SUITE 600
PENSACOLA, FL 32502
For the Plaintiffs

Carol Farrell, Official Court Reporter
cfarrell.crr@gmail.com
856-318-6100

Proceedings recorded by mechanical stenography; transcript
produced by computer-aided transcription.

1 this and that. The Court is very, very seriously considering
2 requiring Teva to produce all nonresponsive documents to the
3 plaintiffs. Now, if I was the plaintiffs and if I was a
4 rational person, I'm not sure I would want that, because if
5 this CAL or CMLL is as good as everybody says it supposedly
6 is, they're wasting enormous amounts of time. But if that's
7 what the plaintiffs want, given the fact that we negotiated
8 nine months or so over search terms, and on July 1st, they
9 find out for the first time that TAR is going to be used, if
10 that's what the plaintiffs want, the Court is very seriously
11 considering giving it to them. That being said, if I was the
12 plaintiffs, I wouldn't do that because it's just an
13 incredible, it sounds like just an incredible -- I don't want
14 to say waste -- devotion of resources. So I agree with
15 Mr. Slater that, hopefully, the proposal as to plaintiffs that
16 Teva is going to make is like *The Godfather*. Here's an offer
17 you can't refuse. Right? I think it's in everyone's best
18 interests to make as full a disclosure to plaintiffs as
19 possible. And, frankly, I'm not the expert in this area, you
20 are, but if Teva is saying that this program is so good and
21 it's better than humans, and we can identify nonresponsive
22 documents, frankly, I don't understand why they have to review
23 them in person by a human before they produce them to
24 plaintiffs. Because if they're so confident that this system
25 works, just give plaintiffs the documents. There will be a